Arbutus Biopharma Corporation (NASDAQ:ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, mainly chronic hepatitis B virus (cHBV) and coronaviruses (including COVID-19). To address HBV, we are developing a RNAi therapeutic, an oral PD-L1 inhibitor, and an oral RNA destabilizer to potentially identify a combination regimen with the aim of providing a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. To treat COVID-19 and future coronavirus outbreaks, we are focused on pursuing a combination therapy consisting of compounds that inhibit two essential viral proteins, the SARS-CoV-2 nsp5 main protease (Mpro) and nsp12 viral polymerase, to achieve better patient treatment outcomes and use in prophylactic settings.